top of page
LinkedIn cover - 3.png

OUR JOURNEY

We are committed to developing effective therapies for critically ill patients with sepsis and septic shock.

OUR MISSION

Saving lives, worldwide

Sepsis accounts for 20% of all global deaths and is the biggest killer in intensive care units in Australia and worldwide.

​

We have been studying the complex pathophysiology of sepsis over the last 20 years to develop targeted treatments. Our patented drug is showing promising improvements in blood pressure management and multi-organ function in preclinical and clinical sepsis.

​

A therapy that is safe and rapidly reverses multi-organ dysfunction in sepsis will save millions of lives each year.

MEGASCORES-project-team-728x520.jpg

Our Journey So Far

2002 - 2013

PRECLINICAL

Clinically Relevant Sepsis Model Development

2013 - 2018

PATHOPHYSIOLOGY OF SEPSIS

Elucidation of the pathophysiology of sepsis and targeted drug development

Our Scientific and Clinical Leadership Team

Our team is comprised of leading scientists and clinicians from top medical research institutes and public hospitals across Australia.

Publications

Yanase, F., Spano, S., Maeda, A. et al. Mega-dose sodium ascorbate: a pilot, single-dose, physiological effect, double-blind, randomized, controlled trial. Crit Care 27, 371 (2023). https://doi.org/10.1186/s13054-023-04644-x

May CN, Bellomo R, Lankadeva YR. Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19. Br J Pharmacol. 2021 Oct;178(19):3864-3868. doi: 10.1111/bph.15579. Epub 2021 Jun 24. PMID: 34061355; PMCID: PMC8239596.

Lankadeva YR, Peiris RM, Okazaki N, Birchall IE, Trask-Marino A, Dornom A, Vale TAM, Evans RG, Yanase F, Bellomo R, May CN. Reversal of the Pathophysiological Responses to Gram-Negative Sepsis by Megadose Vitamin C. Crit Care Med. 2021 Feb 1;49(2):e179-e190. doi: 10.1097/CCM.0000000000004770. PMID: 33239507; PMCID: PMC7803449.

Lankadeva YR, Lane DJ, Ow CP, Story DA, Plummer MP, May CN. LOVIT or leave it: The vitamin C debate continues. Crit Care Resusc. 2023 Jun 27;25(2):63-64. doi: 10.1016/j.ccrj.2023.05.001. PMID: 37876602; PMCID: PMC10581254.

bottom of page